

Date 13/04/2026  
Your Ref  
Our Ref 11296

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – ANTI-CANCER THERAPIES

I write in response to your request for information in relation to anti-cancer therapies.

Question:

1. How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

Answer:

There were 64 patients.

Due to the setup of the disease tree on chemocare, we have been unable to separate the Gastro-Oesophageal Junction and Gastric cancer diagnoses. This means the data in Q1 contains data for the below diagnoses. Q2 contains data for both Q2 & Q3 again as we are unable to separate the diagnosis from the database.

Question:

2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:
  - a. CAPOX (Capecitabine with Oxaliplatin)
  - b. FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
  - c. Lonsurf (Trifluridine - tipiracil)
  - d. Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - e. Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - f. Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - g. Zolbetuximab (Vyloy)
  - h. Any other systemic anti-cancer therapy
  - i. Palliative care only

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common  
name of Lothian Health Board*

Question:

3. How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:
- CAPOX (Capecitabine with Oxaliplatin)
  - FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)
  - Lonsurf (Trifluridine - tipiracil)
  - Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - Pembrolizumab (any formulation) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - Pembrolizumab (395 mg or 790mg solution for injection only) in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
  - Zolbetuximab (Vyloy)
  - Any other systemic anti-cancer therapy
  - Palliative care only

Answer:

2a	5<
2b	Nil
2c	Nil
2d	6
2e	5<
2f	Nil
2g	Nil
2h	62
2i	N/A

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

4. If you have been unable to answer any of the above questions because you do not treat Gastric or Gastro-Oesophageal Cancer, to which site do you refer patients that require either treatment?

Answer:

Not applicable

I hope the information provided helps with your request.



If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive